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Abstract
OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve 
survival in adults hospitalized with influenza. We analyzed California surveillance data to 
determine whether NAI treatment improves survival in critically ill children with influenza.
METHODS: We analyzed data abstracted from medical records to characterize the outcomes of 
patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 
2009, through September 30, 2012.
RESULTS: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had 
information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic 
(April 3, 2009–August 31, 2010) received NAI treatment compared with 63% (121 of 193) of 
cases in the postpandemic period (September 1, 2010–September 30, 2012; P < .0001). Of 653 
cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 
95% confidence interval: 0.34–1.36). In a multivariate model that included receipt of mechanical 
ventilation and other factors associated with disease severity, the estimated risk of death was 
reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16–0.83). Treatment 
within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with 
NAI treatment initiated earlier in illness were less likely to die.
CONCLUSIONS: Prompt treatment with NAIs may improve survival of children critically ill 
with influenza. Recent decreased frequency of NAI treatment of influenza may be placing 
untreated critically ill children at an increased risk of death.
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Influenza A(H1N1)pdm09 (pH1N1) virus was first identified in California in April 2009 and 
caused a global pandemic1-3 that disproportionately affected children and young adults.2 As 
a result, in April 2009, the California Department of Public Health (CDPH) initiated 
surveillance for critically ill and fatal cases of laboratory-confirmed influenza.
During the pH1N1 pandemic, the reported morbidity and mortality in California were high, 
with 2144 persons admitted to an ICU and 608 deaths, including 45 deaths in persons aged 
<18 years. In the first few months of the pandemic, national hospitalization rates for 
laboratory-confirmed pH1N1 were 4.5-fold higher among children aged <2 years, 2-fold 
higher among children aged 2 to 4 years, and 1.6-fold higher among children aged 5 to 17 
years than among adults.4 In California, during April 3 through August 11, 2009, of 345 
persons hospitalized aged <18 years with laboratory-confirmed influenza, more than one-
quarter of these hospitalized cases required intensive care, and 9 (3%) were fatal.5 Infants 
aged <6 months were most likely to be hospitalized.
Since the onset of the pH1N1 pandemic, prompt initiation of antiviral treatment has been 
recommended for all patients with suspected or confirmed influenza (1) requiring 
hospitalization; (2) in a high-risk group with comorbidity associated with severe disease as 
defined by the Advisory Committee for Immunization Practices (ACIP), including children 
aged <2 years; and (3) with complicated illness regardless of previous health status.6,7 The 
neuraminidase inhibitors (NAI) currently available for treatment include enteral oseltamivir 
phosphate, inhaled zanamivir,8 and the investigational intravenous formulations of peramivir 
and zanamivir. During the pH1N1 pandemic, the Food and Drug Administration issued 
Emergency Use Authorizations to treat hospitalized children <1 year old with enteral 
oseltamivir and to allow intravenous peramivir for treatment of hospitalized patients. In 
December 2012, the Food and Drug Administration approved use of enteral oseltamivir for 
treatment of symptomatic infants aged ≥14 days that are suspected of having influenza and 
that have had symptoms for <48 hours (http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm333205.htm). However, the ACIP and Centers for Disease Control 
and Prevention recommendations also include oseltamivir treatment of influenza in infants 
aged <14 days.8
The clinical efficacy and safety of oseltamivir for severe influenza in hospitalized patients 
have been questioned because data from phase 3 treatment trials remain unavailable for 
review.9 Several observational studies have demonstrated a reduction in outcomes such as 
length of hospital stay and risk of critical illness requiring ICU admission or death among 
hospitalized adults treated with NAIs before, during, and after the pH1N1 pandemic.10-19 
However, relatively few studies have evaluated the effectiveness of antiviral treatment of 
influenza in hospitalized children. We previously found that in cases aged <18 years 
hospitalized with pH1N1, those treated with NAIs within 48 hours of symptom onset were 
less likely to require ICU admission or die compared with those never treated.5 In this study, 
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we analyzed antiviral treatment and survival of children aged 0 to 17 years admitted to ICUs 
with laboratory-confirmed influenza reported to CDPH during the pandemic and in the 2 
subsequent postpandemic influenza seasons.
METHODS
CDPH instituted mandatory reporting for all Californians who were hospitalized or died 
with influenza from April 3 through August 10, 2009. From August 11, 2009, through 
September 30, 2012, requirements were changed for mandatory reporting of all Californians 
aged 0 to 64 years with laboratory confirmed influenza who died; reporting became 
voluntary for Californians aged 0 to 64 years with laboratory-confirmed influenza that 
required care in an ICU. For the purposes of this study, a case was defined as a California 
resident aged 0 to 17 years that had influenza virus nucleic acid detected in a respiratory 
specimen of any type by reverse-transcription polymerase chain reaction assay and was 
hospitalized in an ICU with signs and symptoms of acute respiratory infection. Fatal cases 
had influenza listed as a cause of death in either the death certificate or medical record. 
Testing was performed at local public health laboratories, commercial laboratories or the 
CDPH Viral and Rickettsial Disease Laboratory. Providers and hospitals reported cases to 
local health jurisdictions, which then reported cases to CDPH. Using a standardized case 
report form local health jurisdiction and CDPH staff abstracted data from medical and 
autopsy records regarding demographics, clinical presentation, and hospital course, 
comorbid conditions, laboratory results and type, and dosing and dates of antiviral 
medications.
Nonfatal and fatal patients were compared with respect to demographics, clinical 
characteristics, and underlying risk factors. The χ2 test was used for comparisons of 
categorical variables with large numbers and Fisher’s exact test was used for comparisons of 
categorical variables with expected values <5. The Wilcoxon 2-sample test was used for 
comparisons of continuous variables. To better understand and visually inspect the 
confounding effect of clinical severity on the relationship of treatment with survival, 
bivariate Mantel-Haenszel adjustment was conducted and graphically assessed. Variables 
that may increase the severity of clinical illness that were significantly associated with 
fatality in univariate analysis were incorporated into a multivariable logistic regression 
model. Case fatality proportions were determined for cases categorized by numbers of days 
from onset of symptoms to initiation of antiviral therapy and were compared with those who 
were never treated with antiviral agents. The Cochran-Armitage test for trend was used to 
assess the association of survival with the time between symptom onset and initiation of 
antiviral treatment. All analyses were performed by using SAS 9.2 (SAS Institute, Cary, 
NC).
This activity was reviewed by the State of California Committee for the Protection of 
Human Subjects and determined to be a public health response that did not require 
institutional review board approval.
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RESULTS
During the period of April 3, 2009, to September 30, 2012, 850 California residents aged 0 
to 17 years who required intensive care or died with laboratory-confirmed influenza were 
reported. Of these, 827 (97%) were hospitalized in ICUs, and 23 (3%) died outside of the 
hospital. Overall, 784 (95%) of the hospitalized patients had information available on 
antiviral treatment and were analyzed.
Pandemic Versus Postpandemic
The majority of patients reported during the pandemic (April 3,2009–August 31, 2010) had 
test results consistent with pH1N1 virus infection (90%; 531 of 591). Influenza virus testing 
during the postpandemic period (September 1, 2010–September 30, 2012) was consistent 
with pH1N1 in 22% (42 of 192), influenza A subtype H3 in 22% (42 of 192), nonsubtyped 
influenza A in 28% (53 of 192), and influenza B in 28% (53 of 192). Overall, 532 (90%) of 
591 patients reported during the pandemic received NAI treatment during their illness 
compared with 121 (63%) of the 193 cases in the postpandemic period (P < .0001). The 
interval from symptom onset to NAI treatment was similar for patients hospitalized in the 
pandemic period (median 3 days, range 0–33 days) and the postpandemic period (median 3 
days, range 0–21 days; P = .2).
Demographic and Clinical Characteristics
Four hundred seventy-three patients (61%) were boys. The median age was 6 years (range 0 
weeks-17 years). Five hundred twenty-one cases (68%) had a comorbid condition 
considered by the ACIP as increasing the risk of severe influenza complications20; nearly 
half of cases had chronic pulmonary disease (366; 48%). Other frequently reported chronic 
medical conditions included neurologic disorders such as cerebral palsy/developmental 
delay and seizure disorder (277; 36%), chronic cardiac disease (105; 14%), and 
immunosuppression (77; 10%). The median length of hospital stay was 6 days (range 1–238 
days). The median timeframes from symptom onset to hospitalization and intensive care 
admission were 2 days (range 0–32 days) and 3 days (range 0–372 days), respectively.
Forty-nine (6%) children died. Compared with nonfatal patients, fatal patients were more 
likely to have an ACIP comorbid condition (P = .005), radiographic evidence of pneumonia 
(P = .0007), and require mechanical ventilation (P < .0001; Table 1). There was no 
significant difference in distribution by gender, race/ethnicity, or age in the nonfatal 
compared with fatal cases; younger children (either <2 or <4 years) were not at increased 
risk for death.
NAI Treatment
Of the 784 patients, 653 (83%) were treated with NAIs and 131 (17%) were not. The overall 
median duration of NAI treatment was 5 days (range 0–16 days). Of the 653 treated patients, 
38 (6%) died compared with 11 (8%) of 131 untreated patients (odds ratio [OR] = 0.67, 95% 
confidence interval [CI]: 0.34–1.36). In bivariate analysis stratifying on mechanical 
ventilation, antiviral therapy was significantly associated with decreased mortality (OR = 
0.38, 95% CI: 0.17–0.87) but not in similar stratification on pneumonia (OR = 0.64, 95% CI: 
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0.29–1.38). In a multivariate model that incorporated variables that were significant in the 
univariate analysis, receipt of antiviral therapy was associated with decreased mortality (OR 
= 0.36, 95% CI 0.16–0.84; Table 1).
Timing of NAI Treatment
For the 591 (91%) cases with available information on timing of antiviral treatment, the 
median time from onset of symptoms to starting NAI treatment was 3 days (range 0–33 
days). Of treated cases, 502 (84.9%) began treatment during their first week of illness, 66 
(11.2%) during the second week and 23 (3.9%) were treated subsequently (Fig 1). Of 255 
cases treated with an NAI within 48 hours of symptom onset, 9 (3.5%) died compared with 
11 (8%) of 131 untreated cases (P = .04). There was a significant difference between the 
median time from onset of symptoms to treatment of nonfatal cases (median 3 days, range 
0–33 days) compared with fatal cases (5 days, range 0–29 days; P = .004). Early treatment 
with NAIs sooner after illness onset was associated with decreased mortality (Fig 1; test for 
trend P = .0002).
DISCUSSION
We reviewed available epidemiologic and clinical data for >780 critically ill children with 
laboratory-confirmed influenza in California over a 3-year period during and after the 
pH1N1 pandemic. Patients treated with NAIs were less likely to die compared with 
untreated patients (6% compared with 8%, respectively), suggesting NAI treatment was 
beneficial [OR = 0.67, 95% CI: 0.34–1.36). The risk of death in patients requiring 
mechanical ventilation was much higher, even when treated (OR = 81.9,95% CI: 11.2–
597.4). In a multivariate model that included receipt of mechanical ventilation and other 
factors associated with disease severity, the risk of dying was reduced for cases treated with 
NAIs (OR = 0.36, 95% CI: 0.16–0.84). Timing of NAI treatment was important: children 
treated earlier in their illness were less likely to die than those who were treated later, and 
cases treated within 48 hours of illness onset were significantly more likely to survive 
compared with those never treated.
There is strong evidence that NAI treatment of hospitalized adults is beneficial when 
initiated early in the clinical course of influenza, although evidence from randomized 
placebo-controlled trials is lacking.20 In large observational studies, hospitalized adults 
infected with seasonal, pH1N1 or influenza A (H5N1) viruses were less likely to die or 
require intensive care when NAIs were initiated no later than 4 days from onset of 
symptoms.10-19 Initiation of NAI treatment within 5 days of symptom onset increased the 
likelihood of survival in a study of >1800 adults hospitalized in ICUs in California.21 A 
recent meta-analysis reviewing data from 90 studies of adults and children with pH1N1 
found NAI treatment within 48 hours of symptom onset reduced the likelihood of severe 
outcomes such as death and ICU admission.22
There are fewer and less consistent data on the effectiveness of NAI treatment of influenza 
in hospitalized children, with some studies finding no association with improved survival. 
Early NAI use in hospitalized children has been associated with a decreased likelihood of 
ICU admission and need for mechanical ventilation; mortality was not assessed in these 
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studies.23,24 A study of 287 hospitalized, previously healthy children found no difference in 
length of stay, diagnosis of pneumonia, ICU admission or death in NAI-treated compared 
with untreated patients; however, the young age of patients (40% aged <6 months) may have 
prompted hospitalization for observation purposes rather than because of severity of illness.
25
 A retrospective cohort study of >500 children with severe seasonal influenza illness 
admitted to PICUs over 6 influenza seasons (2001–2007) found that patients treated with 
oseltamivir within 24 hours of hospital admission had an 18% reduction in total hospital 
days (P = .02) but no significant reduction in length of PICU stay, in-hospital mortality, and 
readmission rates.26
In contrast, a handful of small studies have suggested that early NAI treatment improves 
survival. During the initial phase of the 2009 H1N1 pandemic, initiation of oseltamivir 
within 48 hours of symptom onset was associated with a decreased likelihood of ICU 
admission or death (P = .02) in 345 children hospitalized in California.5 Oseltamivir 
treatment initiated within 24 hours of hospitalization was protective against death (P = .02) 
for 147 critically ill children in Argentina.27 Delayed initiation of oseltamivir increased the 
likelihood of death for 193 children hospitalized with highly pathogenic avian influenza A 
(H5N1) virus infection, with a 75% increase in the adjusted OR for death for each day of 
delay.28 Likewise, our review of nearly 800 critically ill children with influenza patients 
suggests improvement in survival with prompt NAI treatment.
Of note, frequency of NAI treatment in our ICUs was 90% during the pandemic but fell to 
63% in the following 2 years. A reduction in antiviral treatment since the 2009 H1N1 
pandemic has also been noted through population-based surveillance for hospitalized 
children with influenza in 10 US states; 84% of children admitted to an ICU with laboratory-
confirmed influenza received antiviral treatment during the 2009 H1N1 pandemic compared 
with 73% during the 2010–2011 season.29 Among all hospitalized pediatric influenza 
patients, there was a 27% decline in the proportion treated with antiviral agents from 2009 to 
2010–2011.29 These results and our findings suggest that further efforts are needed to 
educate clinicians to increase antiviral treatment in hospitalized children with seasonal 
influenza, including those who are critically ill.
We note some important limitations and observations. There was likely under-reporting of 
pH1N1 cases ascertained from voluntary passive reporting by clinicians. In this 
observational study design in which antiviral treatment was not randomized, selection bias is 
always possible, and the treated versus untreated groups may have varied in clinical severity. 
Compared with untreated cases, children treated with NAIs experienced longer median 
length of hospital stay and higher frequency of mechanical ventilation; it is possible that 
clinicians might have been more likely to treat the most relatively critically ill patients with 
NAIs than others admitted to ICUs (eg, nonventilated patients). If the patients who received 
NAIs were more severely ill before treatment, our estimates of the effect of NAI treatment 
are biased toward lack of benefit. Delays in initiating therapy with NAIs may also have 
reduced their effectiveness; 15% of cases began therapy at least 1 week after onset of 
influenza illness. Approximately 6% of data in our multivariable model were missing; we 
performed a sensitivity analysis to check the impact and found little difference in the 
analysis results.
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Additionally, we were unable to analyze other treatment modalities or clinical complications 
that may have affected outcomes despite treatment with NAIs; for example, systematic 
testing for bacterial coinfections was not performed for all cases, and we did not have 
available information on coadministration of corticosteroids, which have been implicated in 
more severe outcomes in hospitalized influenza cases.30 Finally, our results likely represent 
patients infected with influenza viruses susceptible to NAIs because only 3 of 423 cases 
tested in California during this surveillance period were infected with influenza viruses 
containing the H275Y mutation in neuraminidase, which confers resistance to oseltamivir 
(CDPH, unpublished data).
Our results suggest that prompt NAI therapy in children with influenza virus infection who 
are hospitalized in an ICU may improve survival, including in those most severely ill who 
require mechanical ventilation. These findings also emphasize the need for, and the 
difficulty in obtaining, better evidence of the efficacy and optimal timing of NAI therapy in 
children; large randomized controlled trials of NAIs could provide better evidence, but at 
great expense, and present ethical issues because current guidelines recommend initiation of 
NAI treatment as soon as possible in hospitalized children with influenza.7 Nevertheless, 
prompt initiation of NAIs seems prudent in a critical care setting where the likelihood of 
severe morbidity and mortality outweighs concern for side effects. This message needs 
additional emphasis given that in this study, more than one-third of critically ill children with 
influenza did not receive antiviral treatment in the postpandemic period.
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WHAT’S KNOWN ON THIS SUBJECT: Few data on treating children hospitalized 
for influenza with neuraminidase inhibitors are available, contributing to uncertainty 
regarding the benefits of treatment.
WHAT THIS STUDY ADDS: This study of nearly 800 critically ill children suggests 
that treatment with neuraminidase inhibitors improves survival from influenza. This 
message needs additional emphasis, given that in the past 2 seasons over one-third of 
cases did not receive antiviral treatment.
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FIGURE 1. 
Mortality over time in critically ill children aged 0 to 17 years with laboratory-confirmed 
influenza in California, with and without NAI treatment, April 2009 through September 
2012. Note that all fatal cases received mechanical ventilation before death.
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